Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX-115 SAD in Elevated Uric Acid
NCT05745727Phase 1Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gout comparing PRX-115 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events, Number of participants with abnormal clinically significant clinical laboratory results and 3 more. Started Mar 2023; status: completed.
02
Drugs
prx-115
03
Conditions
gout
Beyond the preview
Go deeper on NCT05745727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745727.